Overview


According to FutureWise analysis the market for Antibody Fragments in 2023 is US$ 8.04 billion, and is expected to reach US$ 12.93 billion by 2031 at a CAGR of 6.10%.

Fragment antibodies are fragments of the binding end of a monoclonal antibody (mAb) and are a small but powerful tool to fight disease. While mAbs range from around 150kDa, fragment antibodies are as small as 3kDa and are used in various applications. Their small size helps access difficult-to-reach therapeutic targets on tissues and cells and penetrate tumors more effectively. These small fragments can also be useful for rapidly blocking signaling molecules or receptors. Fragments can also minimize other downstream effects on the immune system because they do not have the bulk of a whole antibody. Fragment antibodies are emerging as great tools in imaging and diagnostics because they are capable of detecting cellular proteins with high affinity and specificity. They can be linked to radioisotopes, fluorescent molecules, or enzymes that tag specific patient biomarkers. They also have a shorter half-life in the body, which results in faster clearance and may result in fewer risks of side effects from potentially invasive diagnostic agents. 

There are two groups of antibody fragments of primary interest: (a) antigen-binding fragments such as Fab and (b) class-defining fragments like Fc that do not bind antigen. Several antigen-binding fragments are viable, but each contains at least the variable regions of heavy and light immunoglobulin chains (VH and VL) held together, usually by disulfide bonds, to preserve the antibody-binding site. Fc fragments comprise the heavy chain constant region (Fc region) of immunoglobulin and play a vital role in mediating cellular effector functions.

FutureWise Market Research has published a report that provides an insightful analysis antibody fragments market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, antibody fragments market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Biogen Inc.
  • Eli Lilly and Co.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Antibody Fragments Market:

  • In June 2022, the FDA gave approval for Beovu (brolucizumab-dbl), an antibody fragment, for use in the treatment of individuals suffering from diabetic macular edema (DME). This approval observed a significant milestone in the field, as Beovu represents a new generation of biologic therapies that target specific proteins involved in the pathology of DME. 
  • In June 2022, Amgen Inc. received FDA approval for RIABNI™ (rituximab-arrx), an antibody fragment used to treat mild to severe rheumatoid arthritis in adults. This milestone approval signifies a significant advancement in the field of rheumatoid arthritis treatment, as RIABNI™ represents a novel approach using antibody fragments to target specific pathways involved in the disease's progression.

The growing incidences of chronic disorders such as cancer, autoimmune disorders, and infectious diseases are expected to drive the antibody fragment market significantly. Their unique specificity allows targeted treatment, enhancing disease-causing agents with accuracy. Moreover, they exhibit reduced side effects compared to traditional therapies, potentially alleviating the effect of adverse reactions on patients' well-being. These advantages set antibody fragments as a captivating option against these significant health concerns, delivering more effective and modest treatments in the future. In addition, technological advancements in monoclonal antibody (mAb) have revolutionized the field of antibody fragments by developing highly potent and targeted therapies. These advancements involve engineering mAb with enhanced binding affinity to cancer-specific antigens, reducing off-target effects and increasing the therapeutic range. Also, innovations in linker chemistry and payload delivery have improved drug release within target cells, enhancing the overall efficiency of antibody fragments and further propelling the market growth. However, high competition from other biologics, including full-sized antibodies, peptides, and small molecules, may face significant hindrances to market growth. Each alternative brings distinct benefits and applications, adding complexity to the decision-making process. So, the choice may rely on a complex evaluation, considering necessary factors such as the precision of target credit, mode of action, and large-scale production service. Thus, this intense competition and the need to asses these variables pose significant constraints on adopting biologic drugs, further hampering the antibody fragments market.

By Product Type

  • F(ab) Fragment
  • F(ab’)2 Fragment

By Disease Indication

  • Cancer
  • Immunodeficiencies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Owing to factors such as the expansion of the regional pharmaceutical industries, the increasing prevalence of immunodeficiency diseases cancer has increased demand for antibody fragments for research purposes. Also, well-established healthcare infrastructure, an increase in clinical trial numbers, and increased government interest in biologics in the United States are likely to drive the market growth. Moreover, owing to the increasing geriatric population, product approvals, advancements in R&D, presence of major regional players, and growing investments by the key market players have contributed to the market growth in the region during the projection period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the antibody fragments market By Product Type, By Disease Indication and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Antibody Fragments Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antibody Fragments Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antibody Fragments Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antibody Fragments Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. F(ab) Fragment
        2. F(ab’)2 Fragment

  • 8.   Antibody Fragments Market, By Disease Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cancer
        2. Immunodeficiencies
        3. Others

  • 9.   North America Antibody Fragments Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Antibody Fragments Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Antibody Fragments Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Antibody Fragments Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Antibody Fragments Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •       1. Novartis AG
             1.1. Company Overview
             1.2. Product Portfolio
             1.3. SWOT Analysis
             1.4. Financial Overview
             1.5. Strategic Overview
            2. F. Hoffmann-La Roche Ltd.
             2.1. Company Overview
             2.2. Product Portfolio
             2.3. SWOT Analysis
             2.4. Financial Overview
             2.5. Strategic Overview
            3. Johnson & Johnson Services, Inc.
             3.1. Company Overview
             3.2. Product Portfolio
             3.3. SWOT Analysis
             3.4. Financial Overview
             3.5. Strategic Overview
            4. Amgen Inc.
             4.1. Company Overview
             4.2. Product Portfolio
             4.3. SWOT Analysis
             4.4. Financial Overview
             4.5. Strategic Overview
            5. Bristol-Myers Squibb Company
             5.1. Company Overview
             5.2. Product Portfolio
             5.3. SWOT Analysis
             5.4. Financial Overview
             5.5. Strategic Overview
            6. AbbVie Inc.
             6.1. Company Overview
             6.2. Product Portfolio
             6.3. SWOT Analysis
             6.4. Financial Overview
             6.5. Strategic Overview
            7. Takeda Pharmaceutical Company Limited
             7.1. Company Overview
             7.2. Product Portfolio
             7.3. SWOT Analysis
             7.4. Financial Overview
             7.5. Strategic Overview
            8. Sanofi
             8.1. Company Overview
             8.2. Product Portfolio
             8.3. SWOT Analysis
             8.4. Financial Overview
             8.5. Strategic Overview
            9. Biogen Inc.
             9.1. Company Overview
             9.2. Product Portfolio
             9.3. SWOT Analysis
             9.4. Financial Overview
             9.5. Strategic Overview
            10. Eli Lilly and Co.
             10.1. Company Overview
             10.2. Product Portfolio
             10.3. SWOT Analysis
             10.4. Financial Overview
             10.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.   FutureWise SME Key Takeaway Points for Client

Related Market

Fragment-based Drug Discovery Market

Read More
Partner

Our Clients